Evidence-based lifestyle interventions, including weight loss and dietary modification, remain the cornerstone of management
The FDA's guidance on blood donor eligibility focuses primarily on medications that could pose risks to recipients or indicate underlying conditions that would disqualify donation
Retatrutide, also called LY3437943, is being studied as a triple agonist that acts on GLP-1, GIP, and glucagon receptors
The Polycompartment Syndrome: Towards an Understanding of the Interactions Between Different Compartments
Skeletal Muscle Loss: Cachexia, Sarcopenia, and Inactivity. The American Journal of Clinical Nutrition , vol
In a randomized trial using PET-MRI to assess carotid plaque inflammation, semaglutide did not show a significant difference versus placebo on the prespecified primary plaque-inflammation endpointslikely influenced by low baseline inflammatory burden in a well-treated population. How to interpret this: Imaging studies like this are helpful for understanding mechanisms and terminology (e.g., atherosclerotic inflammation, PET-MRI plaque imaging), but they do not establish semaglutide as a direct vascular inflammation imaging reducer in general clinical use based on current evidence. 5) They Improve Kidney Outcomes in High-Risk Populations (Semaglutide) By improving glycemic control and metabolic stress, GLP-1 therapies can reduce kidney risk in susceptible patients